<DOC>
	<DOCNO>NCT00867178</DOCNO>
	<brief_summary>This pilot clinical trial study side effect best way give vorinostat isotretinoin combination chemotherapy see well work treat young patient embryonal tumor central nervous system . Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , isotretinoin , vincristine sulfate , cisplatin , cyclophosphamide , etoposide phosphate , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving vorinostat isotretinoin combination chemotherapy may effective treatment embryonal tumor central nervous system . A peripheral blood stem cell transplant may able replace blood-forming cell destroy chemotherapy . This may allow chemotherapy give tumor cell kill .</brief_summary>
	<brief_title>Vorinostat Combined With Isotretinoin Chemotherapy Treating Younger Patients With Embryonal Tumors Central Nervous System</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To investigate feasibility administer vorinostat ( SAHA ) isotretinoin three day prior concomitant cisplatin base chemotherapy three course induction chemotherapy . II . To describe toxicity administer vorinostat ( SAHA ) isotretinoin three day prior concomitant cisplatin base chemotherapy three course induction chemotherapy . III . To investigate prognostic value histopathological classification biological marker context feasibility study . SECONDARY OBJECTIVES : I . To estimate preliminary response rate approach patient measurable residual disease ( primary site and/or metastatic site ) . II . To estimate disease specific progression-free overall survival , context feasibility study . III . To explore predictive value biological marker cerebrospinal fluid ( CSF ) , plasma , urine tumor material context feasibility study . OUTLINE : INDUCTION THERAPY : Patients receive vorinostat orally ( PO ) daily ( QD ) isotretinoin PO twice daily ( BID ) day 1-4 ; vincristine sulfate intravenously ( IV ) day 4 , 11 , 18 ; cisplatin IV 6 hour day 4 ; cyclophosphamide IV 1 hour day 5-6 ; etoposide phosphate IV 1 hour day 4-6 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients also undergo peripheral blood stem cell ( PBSC ) harvest course . CONSOLIDATION THERAPY : Within 6 week ( 10 week patient re-staged ) completion induction therapy , patient receive carboplatin IV 2 hour thiotepa IV 2 hour day 1-2 . Patients also receive autologous PBSC rescue infusion 6 hour day 4 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . Beginning 3 week later , patient M0 non-desmoplastic medulloblastoma also undergo conformal radiotherapy* tumor bed . NOTE : *Patients supratentorial primary tumor metastatic disease undergo radiotherapy discretion treat physician . MAINTENANCE THERAPY : Beginning 4 week completion radiotherapy immediately completion consolidation therapy , patient receive vorinostat PO QD day 1 , 3 , 5 , 6 , 8 , 10 , 12 , 13 isotretinoin PO BID day 1-14 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Patients must histologically confirm , newlydiagnosed medulloblastoma ( except patient histology localize ( M0 ) desmoplastic medulloblastoma atypical teratoid/rhabdoid tumor [ ATRT ] ) supratentorial primitive neuroectodermal tumor ( PNET ) include pineoblastomas Patients must receive prior therapy surgery and/or steroid Patient must adequate pretrial formalinfixed , paraffinembedded ( FFPE ) tumor material available use biology study central pathology review ; snap frozen tissue available , study chair must contact discuss eligibility Patient must suitable candidate , institutional standard stem cell apheresis Lansky performance score ( LPS = &lt; 16 year age ) &gt; = 30 assess within two week prior registration Absolute neutrophil count ( ANC ) &gt; = 1000/ul ( unsupported ) Platelets &gt; = 100,000/ul ( unsupported ) Hemoglobin &gt; = 8 g/dL ( may support ) Bilirubin &lt; 1.5 time upper limit normal age Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 1.5 time institutional upper limit normal age Serum creatinine = &lt; 1.5 time upper limit institutional normal age glomerular filtration rate ( GFR ) &gt; = 70 ml/min/1.73m^2 estimate GFR ( Schwartz bedside ) &gt; 99 ml/min/1.73m^2 Parents/legal guardian must ability understand willingness sign write informed consent document accord institutional guideline Patients diagnosis atypical teratoid/rhabdoid tumor ( ATRT histology , immunohistochemistry and/or molecular analysis ) desmoplastic M0 medulloblastoma exclude study Patients clinically significant unrelated systemic illness ( serious infection significant cardiac , pulmonary , hepatic organ dysfunction ) , would compromise patient 's ability tolerate protocol therapy would interfere study procedure result Patients receive anticancer investigational drug therapy exclude Patients take valproic acid within 2 week prior initiation treatment exclude Patients inability return followup visit obtain followup study require assess toxicity therapy Patients parabens allergy</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>